Loading
Nosocomial Infections in ICU / Respiratory Viral Infections Research / Pneumonia and Respiratory Infections · Journal article
Infectious Disease Reports · August 18, 2026
A consensus or society position rather than new primary data.
This narrative review synthesizes current evidence on the global epidemiology and burden of upper airway tract infections, identifying them as leading causes of healthcare utilization with substantial clinical and socioeconomic impact, particularly in children, older adults, and low- and middle-income countries. The authors recommend integrated public health strategies combining vaccine access, antimicrobial stewardship, rapid diagnostics, and surveillance, informed by lessons from the COVID-19 pandemic.
Structured narrative review. Global upper airway tract infection disease burden; emphasis on children, older adults, and low- and middle-income countries. Global.
Upper airway tract infections account for an estimated 12.8 billion episodes annually and more than 8 million disability-adjusted life years (DALYs) globally Children experience the highest incidence, averaging 6–8 episodes annually Vulnerable populations (older adults, children) are at increased risk of complications and hospitalization
COVID-19 pandemic demonstrated effectiveness of non-pharmaceutical interventions and altered respiratory infection epidemiology
Clinicians should recognize upper airway tract infections as a major cause of healthcare utilization with substantial cumulative burden, particularly in children and older adults. This review supports implementing antimicrobial stewardship, equitable vaccination programs, and rapid diagnostics as priority interventions, especially in under-resourced settings.
A structured narrative review synthesizing epidemiology, clinical impact, and public health strategies for upper airway infections, offering integrated recommendations for policy and practice rather than reporting original clinical trial data.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize upper airway tract infections as a major cause of healthcare utilization with substantial cumulative burden, particularly in children and older adults. This review supports implementing antimicrobial stewardship, equitable vaccination programs, and rapid diagnostics as priority interventions, especially in under-resourced settings.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Upper airway tract infections (UATIs) are among the most common infectious diseases worldwide, accounting for an estimated 12.8 billion episodes annually and more than 8 million disability-adjusted life years (DALYs). Despite their generally self-limiting nature, their cumulative clinical, socioeconomic, and public health burden remains substantial, particularly in children, older adults, and low- and middle-income countries (LMICs). Methods: We performed a structured narrative review of the peer-reviewed literature and reports from major international health organizations to summarize the current evidence on the epidemiology, etiology, clinical impact, socioeconomic burden, prevention strategies, and future challenges associated with UATIs. Particular attention was given to the influence of antimicrobial resistance, vaccination policies, and lessons learned from the COVID-19 pandemic. Results: UATIs remain one of the leading causes of healthcare utilization worldwide. Children experience the highest incidence, averaging 6–8 episodes annually, whereas vulnerable populations are at increased risk of complications and hospitalization. Marked geographical disparities persist, with LMICs experiencing a disproportionate burden due to limited healthcare access, lower vaccination coverage, and higher complication rates. Inappropriate antibiotic prescribing continues to accelerate antimicrobial resistance, while the COVID-19 pandemic profoundly altered the epidemiology of respiratory infections and demonstrated the effectiveness of non-pharmaceutical interventions. Advances in vaccination, antimicrobial stewardship, rapid diagnostics, and novel therapeutic strategies offer promising opportunities to reduce disease burden. Conclusions: Reducing the global burden of UATIs requires integrated public health strategies combining equitable vaccine access, effective antimicrobial stewardship, strengthened healthcare systems, and sustained surveillance. Lessons learned from the COVID-19 pandemic provide a unique opportunity to improve preparedness for future respiratory outbreaks while addressing persistent regional inequalities in prevention and care.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.